Skye Bioscience (SKYE) Financials

Skye Bioscience logo
$0.70 -0.09 (-11.39%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.65 -0.05 (-6.71%)
As of 11/20/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Skye Bioscience

Annual Income Statements for Skye Bioscience

This table shows Skye Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.84 -3.50 -4.14 -19 1.05 -6.56 -8.52 -19 -38 -31 -56
Consolidated Net Income / (Loss)
-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Net Income / (Loss) Continuing Operations
-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -31 -56
Total Pre-Tax Income
-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Total Operating Income
-4.32 -4.47 -3.86 -4.69 -6.63 -6.29 -7.85 -18 -35 -30 -58
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
4.32 4.47 3.86 4.69 6.63 6.29 7.85 18 35 34 58
Selling, General & Admin Expense
3.74 3.53 3.55 4.36 4.39 4.34 4.92 6.09 7.85 18 16
Research & Development Expense
0.58 0.94 0.31 0.33 2.24 1.94 2.93 6.01 5.82 19 42
Total Other Income / (Expense), net
-0.52 1.29 0.77 -15 7.69 -0.27 -0.67 -1.16 -2.91 3.64 2.24
Interest Expense
- 0.00 0.00 0.69 1.73 0.71 0.65 0.67 2.29 0.75 0.00
Interest & Investment Income
- - 0.00 0.00 0.00 0.00 0.00 0.02 0.10 3.03 1.88
Other Income / (Expense), net
-0.52 1.29 0.77 -14 9.41 0.44 -0.02 -0.52 -0.72 1.36 0.36
Income Tax Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01
Basic Earnings per Share
($0.29) ($0.17) ($0.11) ($0.16) $0.01 ($0.03) ($0.02) ($8.77) ($5.37) ($0.73) ($1.41)
Weighted Average Basic Shares Outstanding
16.94M 18.95M 27.91M 121.15M 135.15M 230.75M 406.60M 2.22M 7.01M 36.49M 39.66M
Diluted Earnings per Share
($0.29) ($0.17) ($0.11) ($0.16) ($0.05) ($0.03) ($0.02) ($8.77) ($5.37) ($0.73) ($1.41)
Weighted Average Diluted Shares Outstanding
16.94M 18.95M 27.91M 121.15M 169.56M 231.42M 406.60M 2.22M 7.01M 36.49M 39.66M
Weighted Average Basic & Diluted Shares Outstanding
16.94M 18.95M 27.91M 121.15M 183.21M 350.01M 495.93M 971.55M 56.13M 30.97M 33.38M

Quarterly Income Statements for Skye Bioscience

This table shows Skye Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.42 -5.02 -7.90 -3.90 -14 -11 -18 -13 -14 -13 -11
Consolidated Net Income / (Loss)
-4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Net Income / (Loss) Continuing Operations
-4.42 -5.02 -7.90 -3.90 -14 -11 -18 -13 -14 -13 -11
Total Pre-Tax Income
-4.42 -5.02 -7.89 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Total Operating Income
-4.09 -6.15 -8.41 -4.97 -11 -12 -18 -13 -15 -13 -11
Total Gross Profit
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses
4.09 6.15 8.41 4.97 15 12 18 13 15 13 11
Selling, General & Admin Expense
2.49 4.21 4.33 4.64 4.55 4.56 3.91 3.91 3.43 4.74 3.87
Research & Development Expense
1.59 1.95 4.08 4.88 7.79 7.20 14 9.36 11 7.94 3.94
Other Operating Expenses / (Income)
- - - -4.55 - - - 0.00 - - 3.25
Total Other Income / (Expense), net
-0.33 1.13 0.51 1.07 0.92 0.66 0.62 0.51 0.45 0.17 0.28
Interest Expense
0.43 0.44 0.45 -0.09 -0.05 0.00 0.00 0.00 -0.00 0.00 0.00
Interest & Investment Income
0.05 0.43 0.96 0.91 0.73 0.62 0.53 0.42 0.31 0.17 0.10
Other Income / (Expense), net
0.05 1.14 -0.00 0.07 0.14 0.04 0.09 0.09 0.14 -0.00 0.18
Income Tax Expense
- 0.00 0.01 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share
($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Weighted Average Basic Shares Outstanding
7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Diluted Earnings per Share
($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Weighted Average Diluted Shares Outstanding
7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Weighted Average Basic & Diluted Shares Outstanding
56.13M 28.07M 30.34M 30.34M 30.97M 30.98M 30.99M 32.06M 33.38M 35.14M 35.42M

Annual Cash Flow Statements for Skye Bioscience

This table details how cash moves in and out of Skye Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
3.01 -3.16 0.16 1.59 -0.02 0.64 6.51 -7.74 9.09 58 -63
Net Cash From Operating Activities
-3.73 -3.55 -3.33 -3.94 -6.03 -6.05 -6.47 -13 -14 -25 -43
Net Cash From Continuing Operating Activities
-3.73 -3.55 -3.33 -3.94 -6.03 -6.05 -6.47 -13 -14 -22 -43
Net Income / (Loss) Continuing Operations
-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Consolidated Net Income / (Loss)
-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Depreciation Expense
0.01 0.01 0.01 0.00 0.00 0.00 0.03 0.11 0.12 0.30 0.72
Amortization Expense
0.59 0.05 0.03 0.06 0.63 0.54 0.59 0.49 0.33 0.60 0.00
Non-Cash Adjustments To Reconcile Net Income
1.36 -0.58 0.05 15 -8.01 -0.13 0.76 6.83 24 6.45 7.23
Changes in Operating Assets and Liabilities, net
-0.84 0.14 -0.32 0.10 0.30 0.09 0.66 -0.69 -0.39 -2.53 4.91
Net Cash From Investing Activities
-0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 5.21 6.60 -0.25 -20
Net Cash From Continuing Investing Activities
-0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 5.21 6.60 -0.25 -20
Purchase of Property, Plant & Equipment
-0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 -0.03 -0.01 -1.60 -0.01
Purchase of Investments
- - - - - - - - - 0.00 -20
Divestitures
- - - - - - 0.00 -0.07 5.53 1.36 0.36
Net Cash From Financing Activities
6.74 0.41 3.51 5.54 6.00 6.70 13 -0.21 16 84 0.03
Net Cash From Continuing Financing Activities
6.74 0.41 3.51 5.54 6.00 6.70 13 -0.21 16 84 0.03
Issuance of Common Equity
0.72 0.00 0.00 3.19 6.00 6.13 13 0.00 4.97 0.00 0.03
Other Financing Activities, net
- - 0.00 - - 0.00 0.02 0.00 12 84 0.00
Cash Interest Paid
0.00 0.00 0.00 0.02 0.37 0.12 0.04 0.33 0.20 0.43 0.00
Cash Income Taxes Paid
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01

Quarterly Cash Flow Statements for Skye Bioscience

This table details how cash moves in and out of Skye Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
-3.87 82 -9.22 -6.71 -8.08 -22 -23 -5.40 -13 2.27 -0.08
Net Cash From Operating Activities
-3.84 -4.71 -7.09 -5.26 -8.17 -9.19 -11 -13 -9.77 -8.56 -7.12
Net Cash From Continuing Operating Activities
-3.84 -4.71 -7.34 -5.02 -4.69 -9.19 -11 -13 -9.77 -8.56 -7.12
Net Income / (Loss) Continuing Operations
-4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Consolidated Net Income / (Loss)
-4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Depreciation Expense
0.03 0.03 0.03 0.07 0.18 0.18 0.19 0.18 0.18 0.17 0.16
Non-Cash Adjustments To Reconcile Net Income
0.41 1.33 1.81 -2.34 5.65 2.20 1.90 1.78 1.39 1.67 4.69
Changes in Operating Assets and Liabilities, net
-0.09 -1.29 -1.52 1.05 -0.78 -0.46 4.79 -2.57 3.11 2.10 -1.19
Net Cash From Investing Activities
-0.01 1.14 -0.03 -1.45 0.09 -13 -12 7.97 -2.80 11 7.14
Net Cash From Continuing Investing Activities
-0.01 1.14 -0.03 -1.45 0.09 -13 -12 7.97 -2.80 11 7.14
Sale and/or Maturity of Investments
- - - - - -13 - - - 11 6.96
Net Cash From Financing Activities
-0.02 86 -2.10 - 0.01 0.00 0.02 - 0.01 -0.07 -0.10
Net Cash From Continuing Financing Activities
-0.02 86 -2.10 - 0.01 0.00 0.02 - 0.01 -0.07 -0.10
Repayment of Debt
-0.03 - - - - 0.00 - - - -0.07 -0.11
Cash Interest Paid
- - - - - 0.00 - - - 0.00 0.00
Cash Income Taxes Paid
- - - - - 0.00 - - - 0.00 0.00

Annual Balance Sheets for Skye Bioscience

This table presents Skye Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
3.51 0.32 0.56 1.96 2.00 2.67 9.86 9.11 12 73 28
Total Current Assets
3.45 0.28 0.56 1.95 1.99 2.66 9.61 8.94 12 71 27
Cash & Equivalents
3.22 0.06 0.26 1.85 1.83 2.47 8.98 1.24 1.26 68 5.88
Short-Term Investments
- - - - - - - - - 0.00 20
Prepaid Expenses
0.16 0.17 0.29 0.09 0.15 0.19 0.55 0.78 0.19 0.20 0.50
Other Current Assets
0.04 0.01 0.00 0.00 0.01 0.00 0.06 0.48 1.12 2.21 0.85
Plant, Property, & Equipment, net
0.01 0.01 0.00 0.00 0.00 0.01 0.09 0.09 0.04 1.43 0.90
Total Noncurrent Assets
0.04 0.03 0.00 0.00 0.00 0.00 0.16 0.08 0.25 0.50 0.32
Other Noncurrent Operating Assets
0.04 0.03 - - - 0.00 0.16 0.08 0.25 0.50 0.32
Total Liabilities & Shareholders' Equity
3.51 0.32 0.56 1.96 2.00 2.67 9.86 9.11 12 73 28
Total Liabilities
3.04 1.77 1.36 18 1.45 2.22 3.99 12 14 4.61 8.29
Total Current Liabilities
0.58 0.66 0.81 16 0.97 0.79 3.91 12 14 4.34 8.21
Short-Term Debt
- 0.00 0.24 - 0.00 0.00 1.97 1.85 4.37 - 0.00
Accounts Payable
0.13 0.27 0.10 0.02 0.14 0.38 0.90 1.79 0.96 0.57 2.03
Accrued Expenses
0.37 0.27 0.20 - 0.00 - 0.00 6.21 6.26 1.82 2.07
Current Employee Benefit Liabilities
- - - - - 0.06 0.34 0.66 0.89 1.11 1.27
Other Current Liabilities
0.08 0.12 0.27 16 0.83 0.34 0.69 1.60 1.06 0.84 2.83
Total Noncurrent Liabilities
2.46 1.11 0.55 1.58 0.48 1.43 0.08 0.00 0.17 0.27 0.08
Other Noncurrent Operating Liabilities
2.45 1.11 0.55 0.22 0.09 0.00 0.08 0.00 0.17 0.27 0.08
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Total Preferred & Common Equity
-0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Preferred Stock
- - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Common Stock
6.11 7.18 9.48 18 33 39 53 64 102 199 207
Retained Earnings
-7.76 -11 -14 -33 -32 -39 -47 -67 -104 -131 -187

Quarterly Balance Sheets for Skye Bioscience

This table presents Skye Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets
16 95 87 82 65 52 41 19 11
Total Current Assets
15 95 87 80 63 51 40 19 11
Cash & Equivalents
5.13 83 74 67 46 24 18 8.15 8.07
Short-Term Investments
- - - - 13 25 17 8.96 2.00
Prepaid Expenses
0.21 0.64 1.10 0.66 0.58 1.26 3.71 1.22 0.42
Other Current Assets
0.87 1.51 2.71 2.65 3.23 0.73 0.90 0.23 0.48
Plant, Property, & Equipment, net
0.06 0.04 0.05 1.52 1.30 1.17 1.03 0.76 0.03
Total Noncurrent Assets
0.26 0.23 0.21 0.21 0.46 0.41 0.37 0.09 0.04
Other Noncurrent Operating Assets
0.26 0.23 0.21 0.21 0.46 0.41 0.37 0.09 0.04
Total Liabilities & Shareholders' Equity
16 95 87 82 65 52 41 19 11
Total Liabilities
14 16 14 5.73 5.54 8.48 8.49 10 12
Total Current Liabilities
14 16 14 5.62 5.32 8.31 8.37 10 12
Short-Term Debt
4.17 4.61 4.86 0.00 - - - 0.25 0.14
Accounts Payable
1.64 1.10 1.08 0.78 1.71 3.22 2.83 3.94 4.28
Accrued Expenses
6.21 6.05 6.05 1.79 1.91 1.81 2.05 2.57 5.42
Current Employee Benefit Liabilities
0.65 0.35 0.56 0.90 0.66 0.87 0.92 0.23 0.69
Other Current Liabilities
1.05 3.38 1.39 2.15 1.04 2.42 2.57 3.41 1.00
Total Noncurrent Liabilities
0.19 0.15 0.13 0.11 0.22 0.17 0.12 0.00 0.00
Other Noncurrent Operating Liabilities
0.19 0.15 0.13 0.11 0.22 0.17 0.12 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1.70 79 73 76 59 44 33 9.01 -0.50
Total Preferred & Common Equity
1.70 79 73 76 59 44 33 9.01 -0.50
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1.70 79 73 76 59 44 33 9.01 -0.50
Common Stock
102 188 190 197 201 203 205 208 210
Retained Earnings
-100 -109 -117 -121 -142 -160 -172 -199 -210

Annual Metrics And Ratios for Skye Bioscience

This table displays calculated financial ratios and metrics derived from Skye Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
19,278,163.00 20,798,163.00 30,970,663.00 133,870,080.00 134,095,247.00 250,074,415.00 476,108,455.00 912,195,626.00 12,338,910.00 30,338,290.00 32,057,461.00
DEI Adjusted Shares Outstanding
19,278,163.00 20,798,163.00 30,970,663.00 133,870,080.00 134,095,247.00 250,074,415.00 476,108,455.00 912,195,626.00 12,338,910.00 30,338,290.00 32,057,461.00
DEI Earnings Per Adjusted Shares Outstanding
-0.25 -0.17 -0.13 -0.14 0.01 -0.03 -0.02 -0.02 -3.05 -1.02 -1.74
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-55.49% 26.73% 1.80% -504.04% 118.49% -255.61% -36.45% -151.68% -92.04% 20.17% -104.30%
EBIT Growth
-77.16% 34.36% 2.66% -498.56% 115.02% -310.57% -34.45% -139.28% -88.28% 18.66% -100.45%
NOPAT Growth
-58.04% -3.55% 13.68% -21.59% -101.61% 33.53% -24.78% -133.34% -89.69% 13.08% -92.64%
Net Income Growth
-77.06% 34.35% 2.64% -520.31% 105.48% -723.74% -29.90% -128.60% -93.23% 29.43% -110.50%
EPS Growth
-7.41% 41.38% 35.29% -45.45% 68.75% 40.00% 33.33% -43,750.00% 38.77% 86.41% -93.15%
Operating Cash Flow Growth
-112.40% 4.70% 6.24% -18.36% -52.88% -0.43% -6.95% -96.82% -9.48% -80.89% -70.63%
Free Cash Flow Firm Growth
23.68% -387.51% 21.51% 448.74% -282.36% 78.37% -4.71% -4.20% -394.10% -12.61% -23.28%
Invested Capital Growth
-321.82% 44.28% 46.60% -1,836.10% 94.40% 34.46% -94.84% -668.41% 12.35% 96.59% -2,063.89%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
12.71% -18.46% 14.06% -44.27% 138.21% -375.74% -15.28% -72.76% 14.69% -30.72% -8.00%
EBIT Q/Q Growth
0.50% -15.63% 13.72% -44.21% 129.60% -539.99% -14.51% -66.74% 14.08% -29.02% -7.90%
NOPAT Q/Q Growth
11.24% 5.14% -1.97% -7.54% -54.98% 7.70% -17.04% -59.37% 13.01% -27.87% -7.84%
Net Income Q/Q Growth
17.28% -15.62% 13.73% -41.13% 110.49% -3,076.48% -13.46% -60.97% 12.69% -25.08% -9.17%
EPS Q/Q Growth
32.56% -30.77% 45.00% -45.45% 50.00% -200.00% 0.00% -448.13% 57.07% -43.14% -9.30%
Operating Cash Flow Q/Q Growth
14.82% 11.26% -80.02% 22.26% -8.83% -4.90% -2.91% -29.49% 6.86% -20.70% -3.84%
Free Cash Flow Firm Q/Q Growth
-199.12% 17.30% -82.75% 98.69% -1,952.86% 73.42% 4.25% 34.37% -22.00% -18.27% 1.95%
Invested Capital Q/Q Growth
16.89% -12.83% 61.45% -43.15% 93.77% 59.88% -13.80% -623.99% 7.34% 61.71% -130.73%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.04% 100.05% 100.05% 100.01% 99.85% 100.02% 100.02% 100.03% 100.01% 100.04% 100.01%
Interest Burden Percent
100.00% 100.00% 100.02% 103.70% 37.90% 112.07% 108.28% 103.43% 106.18% 92.10% 96.74%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-55,492.45% 648.65% 274.93% 234.62% -14.01% -1,313.66% -269.90% -1,364.20% 1,464.81% -80.48% -126.85%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
4,280,093.44% 2,519.68% 791.91% 274.33% -14.01% -1,313.66% -269.90% -1,364.20% 1,464.81% -80.48% -126.85%
Return on Equity Simple (ROE_SIMPLE)
542.61% 109.05% 86.69% 123.34% 191.92% -1,455.39% -145.33% 647.65% 1,765.85% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.02 -3.13 -2.70 -3.28 -6.62 -4.40 -5.49 -13 -24 -21 -41
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-104.97% -2.90% -596.55% -6,045.68% 789.39% -173.53% -75.22% -103.87% -233.43% -14.68% -32.31%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -1,085.39% -31.01% -203.33%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.84 -3.18 -3.09 -19 2.78 -5.85 -7.87 -19 -35 -29 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.24 -3.11 -3.05 -18 3.41 -5.31 -7.24 -18 -35 -28 -57
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 31.93 22.19 4.22 0.00 0.00 1.26 1.20
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 31.93 22.19 4.22 0.00 0.00 1.26 1.20
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 16.64 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 6.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 4.71 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 5.78 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 4.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 -0.29 -0.09 0.71 3.18 0.34 -0.61 -2.05 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 -0.09 0.71 3.18 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-198.65 3.43 0.06 0.03 0.13 -2.49 -1.28 -4.49 2.22 -1.12 -1.07
Leverage Ratio
221.19 -3.91 -0.39 -0.15 -0.26 4.67 1.98 6.64 -4.10 1.28 1.15
Compound Leverage Factor
221.19 -3.91 -0.39 -0.16 -0.10 5.24 2.15 6.87 -4.35 1.18 1.11
Debt to Total Capital
0.00% 0.00% -41.59% -9.58% 41.39% 76.08% 25.19% -159.39% 195.16% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% -41.59% 0.00% 0.00% 0.00% 25.19% -159.39% 195.16% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% -9.58% 41.39% 76.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
289.43% -100.86% -490.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-189.43% 200.86% 631.68% 109.58% 58.61% 23.92% 74.81% 259.39% -95.16% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 -0.08 -0.07 0.11 -0.27 -0.27 -0.10 -0.12 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.01 0.03 -0.42 0.20 0.97 -0.03 0.17 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 -0.07 0.11 -0.27 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 -0.09 -0.41 -0.06 -0.33 -0.36 -0.14 -0.18 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.01 0.15 0.22 0.24 1.28 -0.05 0.25 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 -0.41 -0.06 -0.33 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-4.00 -79.06 -52.02 -61.71 -10.10 -23.98 -4.93 -16.76 -20.83 8.44 -13.44
Noncontrolling Interest Sharing Ratio
7,812.93% -288.45% -188.04% -16.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.94 0.42 0.69 0.12 2.05 3.38 2.46 0.74 0.84 16.32 3.30
Quick Ratio
5.54 0.10 0.32 0.12 1.89 3.14 2.30 0.10 0.09 15.77 3.14
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-0.90 -4.36 -3.43 12 -22 -4.71 -4.93 -5.14 -25 -29 -35
Operating Cash Flow to CapEx
-188,092.28% -31,959.53% -16,949.65% -89,920.50% 0.00% -83,736.25% -7,125.75% -45,417.22% -111,172.73% -1,573.38% -682,232.72%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -5,135.27 17.43 -12.62 -6.67 -7.58 -7.73 -11.10 -38.18 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 -4,994.43 -5.75 -3.49 -8.57 -9.94 -19.16 -6.09 -33.68 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -5,023.90 -5.76 -3.49 -8.58 -10.08 -19.20 -6.10 -35.82 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.79 -1.55 -0.83 -16 -0.90 -0.59 -1.15 -8.83 -7.74 -0.26 -5.71
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.13 1.23 0.72 -15 15 0.31 -0.56 -7.68 1.09 7.47 -5.45
Enterprise Value (EV)
12 7.64 7.45 53 16 8.96 18 15 28 17 -1.70
Market Capitalization
13 6.28 4.71 54 17 10 25 15 34 86 24
Book Value per Share
($0.05) ($0.14) ($0.12) ($0.12) $0.00 $0.00 $0.01 $0.00 ($0.17) $2.25 $0.62
Tangible Book Value per Share
($0.05) ($0.14) ($0.12) ($0.12) $0.00 $0.00 $0.01 $0.00 ($0.17) $2.25 $0.62
Total Capital
0.47 -1.45 -0.57 -14 0.94 1.88 7.84 -1.16 2.24 68 20
Total Debt
0.00 0.00 0.24 1.36 0.39 1.43 1.97 1.85 4.37 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 1.36 0.39 1.43 0.00 0.00 0.00 0.00 0.00
Net Debt
-3.26 -0.10 -0.03 -0.50 -1.45 -1.04 -7.01 0.60 -5.96 -68 -26
Capital Expenditures (CapEx)
0.00 0.01 0.02 0.00 0.00 0.01 0.09 0.03 0.01 1.60 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.39 -0.48 -0.28 -16 -0.81 -0.60 -1.31 -2.58 -8.21 -1.93 -6.85
Debt-free Net Working Capital (DFNWC)
2.87 -0.38 -0.02 -14 1.02 1.88 7.67 -1.33 2.12 66 19
Net Working Capital (NWC)
2.87 -0.38 -0.25 -14 1.02 1.88 5.70 -3.18 -2.25 66 19
Net Nonoperating Expense (NNE)
1.82 0.05 0.39 16 -7.67 2.16 3.03 6.66 13 5.43 15
Net Nonoperating Obligations (NNO)
-3.26 -0.10 -0.03 -0.50 -1.45 -1.04 -7.01 -5.82 -5.60 -68 -26
Total Depreciation and Amortization (D&A)
0.60 0.07 0.04 0.06 0.63 0.55 0.63 0.60 0.45 0.90 0.72
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.29) ($0.17) ($0.11) ($0.16) $0.01 ($0.03) ($0.02) ($0.04) ($5.37) ($0.73) ($1.41)
Adjusted Weighted Average Basic Shares Outstanding
19.90M 25.73M 27.91M 133.91M 135.15M 230.75M 406.60M 555.27M 7.01M 36.49M 39.66M
Adjusted Diluted Earnings per Share
($0.29) ($0.17) ($0.11) ($0.16) ($0.05) ($0.03) ($0.02) ($0.04) ($5.37) ($0.73) ($1.41)
Adjusted Weighted Average Diluted Shares Outstanding
19.90M 25.73M 27.91M 133.91M 169.56M 231.42M 406.60M 555.27M 7.01M 36.49M 39.66M
Adjusted Basic & Diluted Earnings per Share
($0.29) ($0.17) ($0.11) ($0.16) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
16.94M 18.95M 100.08M 121.15M 183.21M 350.01M 495.93M 971.55M 56.13M 30.97M 33.38M
Normalized Net Operating Profit after Tax (NOPAT)
-3.02 -3.13 -2.70 -3.28 -6.62 -4.40 -5.49 -8.47 -24 -23 -41
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -4,635.73 -27.01 1.61 -8.29 -12.08 -28.31 -15.48 -38.48 0.00
NOPAT to Interest Expense
0.00 0.00 -4,050.17 -4.79 -3.84 -6.23 -8.44 -19.27 -10.62 -28.21 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 -4,665.19 -27.02 1.61 -8.30 -12.22 -28.35 -15.49 -40.62 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 -4,079.63 -4.80 -3.84 -6.24 -8.58 -19.31 -10.63 -30.35 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Skye Bioscience

This table displays calculated financial ratios and metrics derived from Skye Bioscience's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
12,338,910.00 28,062,907.00 28,067,907.00 30,338,290.00 30,338,290.00 30,974,558.00 30,984,358.00 30,988,420.00 32,057,461.00 33,378,764.00 35,143,722.00
DEI Adjusted Shares Outstanding
12,338,910.00 28,062,907.00 28,067,907.00 30,338,290.00 30,338,290.00 30,974,558.00 30,984,358.00 30,988,420.00 32,057,461.00 33,378,764.00 35,143,722.00
DEI Earnings Per Adjusted Shares Outstanding
-0.36 -0.18 -0.28 -0.13 -0.46 -0.36 -0.57 -0.41 -0.45 -0.37 -0.31
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
61.42% -26.25% -180.57% 80.78% -173.51% -143.32% -121.12% -175.34% -40.83% -8.34% 40.31%
EBIT Growth
58.98% -32.13% -186.89% 80.17% -160.53% -134.00% -115.97% -169.02% -40.20% -8.17% 40.05%
NOPAT Growth
55.98% -98.45% -195.66% 79.89% -161.02% -91.14% -117.05% -166.96% -39.65% -7.78% 39.37%
Net Income Growth
55.32% 2.86% -153.99% 84.37% -120.51% -121.20% -123.02% -227.19% -48.18% -12.66% 38.80%
EPS Growth
99.58% 86.86% 75.00% 96.85% -733.33% -55.56% -120.00% -220.00% -48.00% -14.29% 38.64%
Operating Cash Flow Growth
21.08% -15.94% -256.13% -29.79% -112.58% -95.10% -51.49% -153.94% -19.50% 6.83% 33.73%
Free Cash Flow Firm Growth
-435.15% -167.28% -265.23% -9.57% -278.19% -466.18% -44.67% 32.67% 66.68% 94.08% 82.84%
Invested Capital Growth
12.35% -18.17% 37.66% 91.74% 96.59% 100.31% 4.64% -259.15% -2,063.89% -29,861.00% -112.25%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
84.59% -25.35% -71.31% 41.92% -119.32% -11.51% -55.68% 27.68% -12.18% 14.22% 14.22%
EBIT Q/Q Growth
83.64% -23.96% -67.85% 41.75% -114.95% -11.34% -54.92% 27.44% -12.02% 14.09% 14.15%
NOPAT Q/Q Growth
83.46% -50.56% -36.63% 40.89% -114.66% -10.25% -55.14% 27.29% -12.30% 14.91% 12.73%
Net Income Q/Q Growth
82.28% -13.57% -57.44% 50.67% -150.02% -13.92% -58.74% 27.63% -13.23% 13.38% 13.77%
EPS Q/Q Growth
99.05% -500.00% -11.11% 50.00% -150.00% -12.00% -57.14% 27.27% -15.63% 13.51% 15.63%
Operating Cash Flow Q/Q Growth
5.18% -22.46% -50.67% 25.81% -55.30% -12.39% -16.99% -24.36% 26.92% 12.37% 16.78%
Free Cash Flow Firm Q/Q Growth
61.14% 24.53% -201.66% -23.85% -34.12% -12.99% 22.92% 42.36% 33.62% 79.93% -123.49%
Invested Capital Q/Q Growth
7.34% -11.44% 40.29% 86.61% 61.71% 109.99% -18,717.77% 49.56% -130.73% -37.34% -32.78%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.04% 100.10% 100.00% 100.00% 100.02% 100.02% 100.00% 100.00% 100.00% 100.03%
Interest Burden Percent
109.40% 100.19% 93.92% 79.61% 92.60% 94.73% 97.06% 96.82% 97.87% 98.68% 99.08%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
1,464.81% -101.20% -130.08% -54.82% -80.48% -47.27% -72.75% -94.31% -126.85% -167.97% -233.87%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -127,847.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
1,464.81% -101.20% -130.08% -54.82% -80.48% -47.27% -72.75% -94.31% -126.85% -167.97% -233.87%
Return on Equity Simple (ROE_SIMPLE)
0.00% -47.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.86 -4.31 -5.88 -3.48 -7.47 -8.23 -13 -9.29 -10 -8.87 -7.74
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-27.31% -1.58% -5.15% -0.97% -6.16% -3.91% -7.67% -6.21% -8.53% -9.56% -10.40%
Return On Investment Capital (ROIC_SIMPLE)
-127.69% -5.16% -7.58% -4.59% -10.96% -13.89% -29.24% -28.28% -52.07% -95.79% 2,185.68%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.04 -5.01 -8.41 -4.90 -11 -12 -18 -13 -15 -13 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.78 -4.74 -8.13 -4.72 -10 -12 -18 -13 -15 -13 -11
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 5.56 3.09 1.56 1.26 0.83 2.97 3.71 1.20 2.28 0.00
Price to Tangible Book Value (P/TBV)
0.00 5.56 3.09 1.56 1.26 0.83 2.97 3.71 1.20 2.28 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-2.05 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.03 -0.29
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
2.22 -1.21 -1.21 -1.12 -1.12 -1.06 -1.09 -1.03 -1.07 -1.11 -1.36
Leverage Ratio
-4.10 1.34 1.38 1.25 1.28 1.16 1.20 1.13 1.15 1.23 1.46
Compound Leverage Factor
-4.48 1.34 1.29 1.00 1.19 1.09 1.16 1.10 1.12 1.22 1.45
Debt to Total Capital
195.16% 5.52% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.70% -40.38%
Short-Term Debt to Total Capital
195.16% 5.52% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.70% -40.38%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-95.16% 94.48% 93.74% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.30% 140.38%
Debt to EBITDA
-0.12 -0.13 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.17 2.44 1.90 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.20
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.18 -0.17 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 0.00
Net Debt to NOPAT
0.25 3.32 2.58 0.00 0.00 0.00 0.00 0.00 0.00 0.41 0.27
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-12.15 15.72 8.13 11.23 9.27 2.73 4.70 2.63 -8.42 -14.84 -28.72
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.84 5.99 6.07 14.19 16.32 11.85 6.09 4.77 3.30 1.78 0.95
Quick Ratio
0.09 5.27 5.18 11.99 15.77 11.13 5.85 4.22 3.14 1.64 0.87
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.95 -2.98 -8.99 -11 -15 -17 -13 -7.50 -4.98 -1.00 -2.23
Operating Cash Flow to CapEx
-54,791.48% -148,007.64% -21,851.14% -346.61% -16,338.36% -145,524.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-9.18 -6.82 -19.98 0.00 0.00 -11,624.48 0.00 0.00 0.00 -454.39 -676.90
Operating Cash Flow to Interest Expense
-8.94 -10.78 -15.76 0.00 0.00 -6,326.09 0.00 0.00 0.00 -3,891.73 -2,158.74
Operating Cash Flow Less CapEx to Interest Expense
-8.95 -10.78 -15.83 0.00 0.00 -6,330.44 0.00 0.00 0.00 -3,891.34 -2,158.74
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-7.74 -8.62 -5.15 -0.69 -0.26 0.03 -4.91 -2.48 -5.71 -7.85 -10
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
1.09 -1.33 3.11 7.66 7.47 8.65 0.24 -1.79 -5.45 -7.87 -5.51
Enterprise Value (EV)
28 351 146 42 17 -9.97 81 86 -1.70 3.66 14
Market Capitalization
34 439 225 119 86 49 130 122 24 21 24
Book Value per Share
($0.17) $2.81 $2.59 $2.50 $2.25 $1.91 $1.41 $1.06 $0.62 $0.27 ($0.01)
Tangible Book Value per Share
($0.17) $2.81 $2.59 $2.50 $2.25 $1.91 $1.41 $1.06 $0.62 $0.27 ($0.01)
Total Capital
2.24 83 78 76 68 59 44 33 20 9.26 -0.35
Total Debt
4.37 4.61 4.86 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.14
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-5.96 -88 -78 -76 -68 -59 -49 -35 -26 -17 -9.92
Capital Expenditures (CapEx)
0.01 0.00 0.03 1.52 0.05 0.01 0.00 0.00 0.00 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8.21 -9.04 -5.66 -2.31 -1.93 -1.52 -6.31 -3.76 -6.85 -8.70 -10
Debt-free Net Working Capital (DFNWC)
2.12 83 78 74 66 58 42 32 19 8.41 -0.43
Net Working Capital (NWC)
-2.25 79 73 74 66 58 42 32 19 8.16 -0.57
Net Nonoperating Expense (NNE)
1.56 0.71 2.02 0.42 2.28 2.87 4.85 3.47 4.02 3.64 3.04
Net Nonoperating Obligations (NNO)
-5.60 -88 -78 -76 -68 -59 -49 -35 -26 -17 -9.92
Total Depreciation and Amortization (D&A)
0.26 0.26 0.28 0.18 0.18 0.18 0.19 0.18 0.18 0.17 0.16
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Adjusted Weighted Average Basic Shares Outstanding
7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Adjusted Diluted Earnings per Share
($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding
7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
56.13M 28.07M 30.34M 30.34M 30.97M 30.98M 30.99M 32.06M 33.38M 35.14M 35.42M
Normalized Net Operating Profit after Tax (NOPAT)
-2.86 -4.31 -5.88 -3.48 -7.47 -8.23 -13 -9.29 -10 -8.87 -7.74
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-9.39 -11.46 -18.68 0.00 0.00 -8,070.88 0.00 0.00 0.00 -5,764.79 -3,298.91
NOPAT to Interest Expense
-6.65 -9.86 -13.07 0.00 0.00 -5,669.21 0.00 0.00 0.00 -4,034.59 -2,347.05
EBIT Less CapEx to Interest Expense
-9.41 -11.47 -18.75 0.00 0.00 -8,075.23 0.00 0.00 0.00 -5,764.41 -3,298.91
NOPAT Less CapEx to Interest Expense
-6.67 -9.86 -13.15 0.00 0.00 -5,673.56 0.00 0.00 0.00 -4,034.20 -2,347.05
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Skye Bioscience remains a pre-revenue biotechnology company with substantial operating losses and ongoing cash burn. Revenue has been reported at zero in each of the periods provided, while quarterly net losses ranged from approximately $3.9 million to $24.9 million. The company’s financial position has weakened materially since 2024, although recent expense reductions have moderated the pace of losses.

  • Operating losses improved in Q2 2026. Net loss was $10.8 million, compared with $12.5 million in Q1 2026, $14.4 million in Q4 2025 and $17.6 million in Q2 2025. Operating expenses also declined to $11.1 million from $12.7 million in Q1 and $18.2 million in Q2 2025.
  • Research and development spending has been reduced. R&D expense fell to $3.9 million in Q2 2026 from $7.9 million in Q1 2026 and $14.3 million in Q2 2025. This reduction contributed to the improvement in the quarterly loss, although it could also reflect changes in development activity.
  • Cash operating burn has moderated from late 2025. Net cash used in operating activities was $7.1 million in Q2 2026, down from $8.6 million in Q1, $9.8 million in Q4 2025 and $13.4 million in Q3 2025.
  • Investment maturities have provided near-term liquidity. Skye received $7.0 million from the sale or maturity of investments in Q2 2026 and $10.9 million in Q1. These proceeds helped offset operating cash outflows, although they represent the use of existing capital rather than internally generated cash.
  • Interest and investment income remains a modest offset to operating costs. Q2 2026 interest and investment income was $103,000, down from $170,000 in Q1 and $313,000 in Q4 2025, reflecting the company’s declining cash and investment balances.
  • Debt exposure is relatively limited but not absent. Short-term debt was $143,000 at June 30, 2026, and the company repaid approximately $107,000 during the quarter. However, accounts payable and accrued expenses totaled nearly $9.7 million, creating significant near-term obligations.
  • Liquidity has deteriorated sharply. Cash and short-term investments totaled approximately $10.1 million at June 30, 2026, down from $17.1 million at March 31, $35.2 million at September 30, 2025, and $95.0 million at June 30, 2024. At the Q2 operating cash-burn rate, this liquidity could support only a limited number of additional quarters without new financing or further spending reductions.
  • The balance sheet entered a deficit-equity position. Total assets were $11.0 million versus $11.5 million of liabilities, resulting in negative shareholders’ equity of approximately $497,000. This compares with positive equity of $9.0 million in Q1 2026 and $43.7 million in Q2 2025.
  • Skye has no reported commercial revenue to fund operations. With zero revenue and recurring quarterly losses, the company remains dependent on its cash reserves, investment maturities and potential future capital raises to finance research, development and general operations.
  • Future dilution and financing risk remain elevated. The company has historically relied on equity financing, including a large equity-related cash inflow in Q1 2024. Continued operating losses, declining liquidity and negative equity increase the likelihood that additional financing could be needed, potentially diluting existing shareholders.

Overall, the latest quarter shows some improvement in expense levels and operating cash burn, but the longer-term trend remains unfavorable. Skye’s cash and investment resources have fallen substantially, liabilities now exceed assets, and the company has yet to generate revenue. Investors should focus on the pace of clinical spending, progress toward commercialization and the company’s ability to secure additional funding.

11/22/26 10:14 AM ETAI Generated. May Contain Errors.

Skye Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Skye Bioscience's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Skye Bioscience's net income appears to be on a downward trend, with a most recent value of -$55.92 million in 2025, falling from -$4.84 million in 2015. The previous period was -$26.57 million in 2024. Check out Skye Bioscience's forecast to explore projected trends and price targets.

Skye Bioscience's total operating income in 2025 was -$58.16 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.16 million

Over the last 10 years, Skye Bioscience's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 11 quarters, Skye Bioscience's cash and equivalents has ranged from $5.13 million in Q3 2023 to $83.34 million in Q1 2024, and is currently $8.07 million as of their latest financial filing in Q2 2026.

Skye Bioscience had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Skye Bioscience's book value per share changed from -0.05 in 2015 to 0.62 in 2025.



Financial statements for NASDAQ:SKYE last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners